PAI Pharma (PAI), a portfolio company of Olympus Partners and a US-based developer, manufacturer, and marketer of oral liquid medicines and Ready-To-Use (RTU) sterile injectables, announced on Thursday the acquisition of Nexus Pharmaceuticals, LLC, an Illinois-based pharmaceutical company specialising in the development and commercialisation of injectable medicines used in critical care, oncology, and other hospital settings.
PAI says that the acquisition marks another significant step in its strategy to build a broader portfolio of essential medicines and expand its presence in the hospital and sterile injectable markets.
Nexus brings an established commercial portfolio of over 20 hospital injectable products, customer relationships, and expertise in developing and commercialising critical therapies. Combined with PAI's experience in Ready-to-Dose oral liquid medicines and growing sterile injectable business, including the recent acquisition of Nivagen and its aseptic manufacturing capabilities in Sacramento, the acquisition is claimed to strengthen PAI's ability to serve hospitals and healthcare providers with a broader range of high-quality pharmaceutical products.
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Guardant Health expands liquid biopsy test with AI-powered epigenomic applications
Nuvation Bio to present at Jefferies Global Healthcare Conference in London
AstraZeneca acquires biotechnology company Omniose to strengthen vaccine capabilities
Valneva reports 94% antibody persistence five years after single-dose chikungunya vaccination
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Energenesis Biomedical presents ENERGI-based approach to space anaemia at TASTI 2026
Janux reports positive Phase 1 data for JANX011, plans autoimmune trials in 2027
Illumina expands MRD research portfolio with ultrasensitive sequencing technology